According to the packet definition, the condition is genetic and non-inheritable and arises from osteoblastic differentiation defects. No gene or inheritance pattern is supplied in this packet, so the specific genetic basis is not characterized here.

The packet supplies no diagnostic-method entries, no GeneReviews chapter and no newborn screening information for this condition, so diagnostic approaches are not described here.

The packet supplies no foundational-therapy entries, no GeneReviews management text and no verified FDA approval records for fibrous dysplasia, so treatment is not described here, which reflects the packet contents only. The packet's orphan-drug listing contains entries whose stated indications concern other conditions, and none is presented as a treatment for fibrous dysplasia.

Natural history and outcome information is not certified in this packet. The definition notes that the condition manifests with pain, deformities and fractures, and pathologic fracture is annotated at 30-79%.

ClinicalTrials.gov records supplied include NCT07870616 (CRANIO-DF, morbidity in adults with craniofacial fibrous dysplasia; Centre Hospitalier Universitaire de Nice; not yet recruiting; 2026-12-01 to 2028-12-01), NCT07654647 (patient-specific 3D-printed titanium implants for facial reconstruction; Latakia University; phase NA; recruiting; 2026-04-26 to 2026-11-01) and NCT07507942 (femoral failure load and fracture risk in fibrous dysplasia of bone/McCune-Albright syndrome; Hospices Civils de Lyon; active, not recruiting; 2025-03-10 to 2027-03-10). One further supplied record with a passed completion date is not described. The FD/MAS Alliance is listed as a patient organization.